natgillin/translations-raw huggingface dataset:
One particular embodiment of the invention is the aqueous pharmaceutical suspension, wherein the preservative system further comprises about 0.06% to about 0.26% of edetate disodium, about 0.01% to about 0.27% of benzoic acid or sodium benzoate, about 0.01% to about 0.30% of sorbic acid or potassium sorbate or about 0.10% to about 1.50% of benzyl alcohol. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 1, naznačena time što sustav konzervansa dodatno sadrži otprilike 0,06 % do otprilike 0,26 % dinatrijevog edetata, otprilike 0,01 % do otprilike 0,27 % benzojeve kiseline ili natrijevog benzoata, otprilike 0,01 % do otprilike 0,30 % sorbinske kiseline ili kalijevog sorbata ili otprilike 0,10 % do otprilike 1,50 % benzil-alkohola.
A method of prevention of obesity, reducing the risk of obesity, treatment of obesity, prevention of diabetes type 2, reducing the risk of occurrence of insulin resistance and improving insulin sensitivity, preventing metabolic syndrome, comprising administering to a subject in need thereof a composition according to claim 1 . 
Nutritivni pripravak prema bilo kojem od prethodnih zahtjeva za uporabu u jednom ili više odabranog između prevencije pretilosti, smanjenja rizika od pretilosti, liječenja pretilosti, prevencije dijabetesa tipa 2, smanjenja rizika od pojave inzulinske rezistencije i poboljšanja osjetljivosti na inzulin, prevencije metaboličkog sindroma, prevencije osteopenije i/ili osteoporoze.
A mouse cell comprising in its genome an endogenous λ light chain immunoglobulin locus comprising a deletion of the endogenous mouse Vλ1-Jλ3-Cλ3-Jλ1-Cλ1 gene cluster and a deletion of a region spanning from Vλ2 to Jλ2 of the endogenous mouse Vλ2-Vλ3-Jλ2-Cλ2-Jλ4-Cλ4 gene cluster. The mouse cell of claim 9, wherein the endogenous λ light chain immunoglobulin locus retains endogenous Cλ2, Jλ4 and Cλ4 gene segments. 
Mišja stanica koja u svom genomu sadrži endogeni lokus imunoglobulina lakog lanca A koji se sastoji od brisanja endogenog mišjeg VM -JX43-C23-JM-CM klastera gena 1 brisanja regije koja se proteže od VA2 do JM2 endogenog mišjeg VA2-V23-JX2-C12-IA4-CI4 klastera gena, naznačena time, što endogeni lokus imunoglobulina lakog lanca X zadržava endogene C22, JA4 1 CH4 genske segmente.
peeling a log in a lathe to form a veneer, wherein the thickness of the veneer is in the range from about 2.5 mm up to about 5 mm; 
– ljuštenja klade blanjalicom kako bi se dobilo furnir, gdje je debljina furnira u rasponu od otprilike 2,5 mm do otprilike 5 mm;
The computer-readable medium of claim 8 wherein the step of adding the compensation signal to a control signal to form a qd control signal comprises the step of adding the compensation signal to a Vqse synchronous frame voltage command in the motor drive system. 
Računalno čitljivi medij u skladu s patentnim zahtjevom 8, naznačen time što korak dodavanja kompenzacijskog signala u kontrolni signal da se formira gd kontrolni signal obuhvaća korak dodavanja kompenzacijskog signala u Vqse naredbu napona sinkronog okvira u sustavu pogona motora (100).
reducing the resulting compound of formula (V) to form a compound of formula (VI): and 
0) ciklizacije spoja formule (VI) da tvori spoj formule (I): HO
A fuel containing a composition according to any of the claims 1 - 6, wherein the composition is contained in a ratio of from 1: 8000 to 1: 12.000, preferably 1: 10.000. 
Gorivo koje sadrži pripravak sukladno bilo kojem od patentnih zahtjeva 1 - 6, pri čemu je taj pripravak sadržan u omjeru od 1: 8,000 do 1: 12,000, preporučljivo 1: 10,000.
A compound of formula I 
Spoj formule I O
A mobile lifting assembly as claimed in claim 1 wherein the forces imparted by the mobile lifting assembly and the structural member across the supporting surface are evenly distributed between said at least one of the supporting members of the body frame and the skid. 
Mobilni sklop za podizanje prema patentnom zahtjevu 10 pri čemu je jedna ili više hidrauličkih pumpi postavljena za prilagodbu nagiba gornjeg okvira (32) potpornja (28) tako da je naprezanje opterećenja mobilnog sklopa za podizanje na podupiruću površinu (30) prilagodivo raspodijeljeno.
The method of item 52 or the compound, the polymorphic form, or the pharmaceutical composition for use according to item 52, or the use of item 52, wherein the dermatitis is allergic dermatitis, atopic dermatitis, dermatitis due to chemical exposure, or radiation-induced dermatitis. 
Spoj, polimorfni oblik ili farmaceutski pripravak za upotrebu prema zahtjevu 11, naznačen time da stanje je dermatitis, koji je alergijski dermatitis, atopijski dermatitis, dermatitis zbog izloženosti kemikalijama, ili dermatitis izazvan zračenjem.
The compound of any one of clauses 33 or 35 to 38, wherein the moiety is 
Spoj bilo kojeg od patentnih zahtjeva 1, 2 ili 9, koji je
Preferably the mixture is heated in step (b) to at least 90° C., generally approximately 110-120° C., more preferably 113-117° C. This ensures that the components are fully dissolved, ensures the matrix components are in a non-crystallising form, and facilitates preparation of a homogeneous mass. 
Poželjno, smjesa je zagrijavana u koraku (b) do najmanje 90%C, generalno približno 110-120%C, poželjnije 113-117*C. Ovo osigurava da su komponente u potpunosti otopljene, osigurava da su komponente matriksa u ne-kristalizirajućem obliku i olakšava pripremu homogene mase.
and R5 are each independently selected from the group consisting of H, C1-C6 alkyl, X, and —C1-C6 alkylene-X, wherein X is selected from the group consisting of: 
R4 1 Rs su svaki neovisno odabrani od skupine koja se sastoji od H, C,-C4 alkila, X 1 -Cy-Cg alkilen-X, pri čemu je X odabran od skupine koja se sastoji od (1) -C;:-Ceg cikloalkila;
Figure 13 is a bottom perspective view of ring of Figure 12; 
Slika 13 je donji prikaz obruča sa Slike 12;
A method of purifying a furin polypeptide or a furin polypeptide derivative having furin biological activity from a protein solution comprising the following steps: 
PATENTNI ZAHTJEVI Postupak za pročišćavanje furin polipeptida ili skraćenog furm polipeptida iz proteinske otopine, b, da sadrži sljedeće korake:
If the full tank of mixture is not used, the remainder most times must be thrown away. 
Ako se ne iskoristi sva količina mješavine iz spremnika, ostatak se najčešće mora baciti.
The supernatant was evaporated under vacuum to dryness and the residue triturated with acetone. 
Prezasićena tekućina ispari se u vakuumu do suhog 1 ostatak se isitni s acetonom.
A combination comprising a compound having Formula I: or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein, W is CRw or N, wherein Rw is selected from the group consisting of 
NaM Na Hi ili njegov stereoizomer, tautomer ili farmaceutski prihvatljiva sol, gdje W je CRy ili N, gdje je Ry odabran iz skupine koja sadrži
A polymorph of the crystalline form of claim 1, characterized by an X-ray powder diffraction pattern including peaks at approximately 11.88 and 16.12 °2θ using Cu Ka radiation, or peaks at approximately 7.82, 11.88, 16.12, and 21.46 °2θ using Cu Ka radiation, or peaks at approximately 7.82, 11.88, 12.68, 16.12, 18.63, 21.46, and 23.74 °2θ using Cu Ka radiation, or by an X-ray powder diffraction pattern substantially similar to that set forth in Figure 9. 
Polimorf kristalnog oblika u skladu s patentnim zahtjevom 1, naznačen time što je za njega karakterističan uzorak difrakcije rendgenskih zraka na prahu sa signalima na približno 11,88 i 16,12 °2θ uz upotrebu zračenja Cu Ka, ili signalima na približno 7,82, 11,88, 16,12, te 21,46 °2θ uz upotrebu zračenja Cu Ka, ili signalima na približno 7,82, 11,88, 12,68, 16,12, 18,63, 21,46, te 23,74 °2θ uz upotrebu zračenja Cu Ka, ili uzorak difrakcije rendgenskih zraka na prahu uglavnom sličan onom prikazanom na Slici 9.
The method of E 37, wherein the antibody or antibody fragment is pegylated. 
Antagonist za uporabu u skladu sa zahtjevom 37, naznačen time, da antitijelo ili fragment antitijela je pegiliran.
a penton protein of SAdV-28, amino acids 1 to 582 of SEQ ID NO: 6; and a fiber protein of SAdV-28, amino acids 1 to 323 of SEQ ID NO: 21; said capsid encapsidating a heterologous molecule carrying a gene operably linked to expression control sequences which direct transcription, translation, and/or expression thereof in a host cell and further comprising the 5' and 3' adenovirus cis-elements necessary for replication and encapsidation. 
Adenovirus koji ima ovojnicu sadrži: hekson protein SAdV-28, amino kiseline 1 do 944 sa SEQ ID NO (identifikacijski broj sekvence): 11; penton protein SAdV-28, amino kiseline 1 do 582 SEQ ID NO: 6; i vlaknasti protein SAdV-28, amino kiseline 1 do 323 SEQ ID NO: 21; spomenuta ovojnica koji enkapsulira heterolognu molekulu koja nosi gen operativno povezan za sekvence koje kontroliraju ekspresiju što regulira transkripciju, translaciju, i/ili ekspresiju istih u stanicu domaćina i dalje sadrži 5’ i 3’ adenovirusne cis-elemente neophodne za replikaciju i enkapsulaciju.
Even the application of microcrystalline cellulose with a low moisture content is not required, since during pelletization the substance mixture is moistened with water or contacted with an aqueous solution or dispersion. 
Čak nije ni nužnost da se koristi mikrokristalna celuloza s malenim sadržajem vlage, jer se tijekom granuliranja smjesa tvari viaži vodom ili dovodi u dodir s vodenom otopinom ili disperzijom.
A compound of formula a pharmaceutically acceptable addition salt; or a stereochemically isomeric form thereof, wherein R1 is halo; 
Spoj formule [image] farmaceutski prihvatljiva adicijska sol; ili njegov stereokemijski izomerni oblik, naznačen time da
The compound or salt of claim 1 wherein R1 is independently selected from the group consisting of chloro, fluoro, and bromo; and X is selected from the group consisting of 
je neovisno odabrana iz skupine koju čine kloro, fluoro, i bromo; i X je odabrana iz skupine koju čine [image]
HYDROPHOBIZED FIBER CEMENT PRODUCT COMPRISING AT LEAST ONE PROFILED SURFACE 
osiguravanje vlaknastog cementnog proizvoda koji sadrži najmanje jednu profiliranu površinu;
Conductive heat exchange relationships can be achieved by locating the aerosol generating means in contact with the fuel element and in close proximity to the burning portion of the fuel element, and/or by utilizing a conductive member to carry heat from the burning fuel to the aerosol generating means. 
Provodljiv odnosi za toplinsku razmjenu mogu se postići postavljanjem sredstva za generiranje aerosola da bude u kontaktu sa gorivim elementom i u velikoj blizini sa gorivim djelom gorivog elementa, i/ili korištenjem provodljivog člana za odnošenje topline sa gorivog djela prema sredstvu za generiranje aerosola.
The methylation-unspecific primer oligonucleotide of item 8 or the kit of any one of items 9-12, wherein the single strand of genomic DNA is of human FOXL2, SHOX2 or PTGER4 DNA, including the respective promoter region, and DNA within 5 kb upstream and downstream thereof. 
Pribor sukladno patentnom zahtjevu 5, pri čemu navedeni lanac genomske DNA dolazi kao humana FOXL2, SHOX2 ili PTGER4 DNA, uključujući odnosnu promotorsku regiju (područje) i DNA unutar 5 kb uzvodno i nizvodno od nje.
The mixing and kneading machine (1) as set forth in claim 1, characterized in that the screw shaft (3) is adapted to be operated at a rotational speed exceeding 800 rpm. 
Stroj za miješanje 1 gnječenje Stroj za miješanje 1 gnječenje (1) sukladno zahtjevu 1, naznačen time što je osovina (3) pokretana rotacijskom brzinom od 500 rpm, posebice višom od 800 rpm.
Accordingly the invention includes a combination of an agent of the invention as hereinbefore described with an anti-inflammatory, bronchodilatory, antihistamine or anti-tussive drug substance, said agent of the invention and said drug substance being in the same or different pharmaceutical composition. 
S tim u skladu izum uključuje kombinaciju sredstva izuma, kako je opisano ovdje ranije, s anti-upalnim, bronhodilatorskim, antihistaminskim ili ljekovitom tvari protiv kašlja, pri čemu spomenuto sredstvo izuma i spomanuta ljekovita tvar mogu biti u istom ili u različitom farmaceutskom sastavu.
System for receiving digital signals comprising a QAM demodulator, characterized in that it is adapted to implement the method according to any one of claims 5 to 6. 
Sustav za primanje digitalnih signala koji sadrži QAM demodulator, naznačen time, da je prilagođen za primjenu postupka u skladu s bilo kojim od patentnih zahtjeva 6 do 8.
Additionally, the compounds of formula (I), especially 2-acetylthioisosorbide 5-mononitrate (12), their tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof, may also be used in a therapy for the prevention and/or treatment of atherosclerosis, cardiac allograft vasculopathy, platelet activation, thrombosis, stroke, pathological conditions where oxidative stress plays an important role in their pathogenesis, and/or tissue damage due to ischemia and/or due to ischemia-reperfusion. 
K tome, spojevi formule (I), posebno 2-acetiltio-izosorbid 5-mononitrat (12), njegovi tautomeri, farmaceutski prihvatljive soli i njegovi solvati mogu se također upotrijebiti u terapiju za prevenciju i/ili liječenje ateroskleroze, kardijalne vaskulopatije alografta, aktivacije trombocita, tromboze, udara kapi, patoloških stanja u čijoj patogenezi ima važnu ulogu oksidativan stres i/ili ozljeda tkiva zbog ishemije i/ili zbog ishemije-reperfuzije.
The granulate is compressed into 125 mg tablets on a suitable tabletting machine 
Granulat je komprimiran u tablete od 125 mg na pogodnom stroju za tabletiranje.
wherein the L1 header includes the L1 TI mode information indicating the time deinterleaving depth of the L1 signaling data; selectively time-deinterleaving the preamble symbols including the at least one L1 TI block by a row-column twisted fashion, wherein the row-column twisted fashion comprises input L1 signaling data cells serially written into an interleaving memory in a diagonal direction, and serially read out row-wise, without considering pilot positions; 
selektivno raspletanje vremena simbola početnog niza uključujući barem jedan L1 TI blok na način prelamanja redova-stupaca, pri čemu način prelamanja redova-stupaca obuhvaća unos u podatkovne stanice signalnih podataka L1 serijski upisane u memoriju umetanja u dijagonalnom smjeru, i serijsko očitavanje u smjeru redova, bez razmatranja pozicija pilota;
The antibody or functional protein comprising an antigen binding portion thereof according to any of claims 1-3, wherein said antibody comprises a full length heavy chain amino acid sequence having at least 95% sequence identity to at least one sequence selected from the group consisting of SEQ ID NOs: 146-150 and 156-160 and wherein said antibody or functional protein comprising an antigen binding portion thereof comprises a full length light chain amino acid sequence having at least 95% sequence identity to at least one sequence selected from the group consisting of SEQ ID NOs:141-145 and 151-155. 
Protutijelo ili funkcionalni protein koji obuhvaća njegov dio koji veže antigen, prema bilo kojem od zahtjeva 1-3, naznačen/o time, da navedeno protutijelo obuhvaća aminokiselinsku sekvencu pune duljine s jakim lancem, koja ima najmanje 95% identiteta sekvence od barem jedne sekvence odabrane iz skupine koju čine: SEQ ID NOs: 146-150 i 156-160, te pritom navedeno protutijelo ili navedeni funkcionalni protein koji obuhvaća njegov dio koji veže antigen, obuhvaća aminokiselinsku sekvencu pune duljine sa slabim lancem, koja ima najmanje 95% identiteta sekvence od barem jedne sekvence odabrane iz skupine koju čine: SEQ ID NOs: 141-145 i 151-155.
Pharmacy, 19(4), 483-491, 1993) in case of the preparation of pellets with high active agent content the application of microcrystalline cellulose containing a slight amount of sodium carboxymethyl cellulose promote the formation of high-quality pellets. 
Pharmacy, 194), 483-491, 1993) u slučaju priređivanja tableta s visokim sadržajem aktivne tvari, primjena mikrokristalne celuloze koja sadrži malene količine natrijeve karboksimetil celuloze pomaže nastajanju vrlo kvalitetnih tableta.
A compound according to claim 1, selected from the group consisting of: 
Spoj prema zahtjevu 1 naznačen time da je odabran iz skupa koji čine:
The infusing step is typically repeated on a cyclic basis, which may be repeated as appropriate over for instance 1 to 20 cycles. 
Korak infuzije se obično ponavlja na cikličnoj osnovi, koji se može ponavljati prikladno u toku, npr. 1 do 20 ciklusa.
An antisense oligomer which is selected from a group consisting of (a) to (c) below, or a pharmaceutically acceptable salt or hydrate thereof: 
PATENTNI ZAHTJEVI Antisensni oligomer odabran iz skupine koja se sastoji od (a) do (c) dolje, ili njegova farmaceutski prihvatljiva sol ili hidrat:
A compound for use as defined in claim 12 wherein said second therapeutic agent is selected from antidiabetic agents, lipid-lowering/lipid-modulating agents, agents for treating diabetic complications, anti-obesity agents, antihypertensive agents, antihyperuricemic agents, and agents for treating chronic heart failure, atherosclerosis or related disorders. 
Spoj za primjenu na način definiran u zahtjevu 12, naznačen time, stoje drugo terapijsko sredstvo odabrano iz antidijabetičkih sredstava, sredstava za snižavanje lipida/sredstava za lipidno moduliranje, sredstava za liječenje dijabetičkih komplikacija, sredstava protiv pretilosti, antihipertenzivnih sredstava, antihiperuricemičnih sredstava i sredstava za liječenje kroničnog zatajenja srca, arterioskleroze ili povezanih poremećaja.
Use according to claims 1 to 4 wherein the composition is up to 60% protective, in a population of vaccinated individuals, against diarrhoea caused by infection of a rotavirus of at least two non-G1 serotypes. 
Upotreba u skladu s patentnim zahtjevima 1 do 5, naznačena time što pripravak štiti do 60% u populaciji osoba cijepljenih protiv proljeva uzrokovanog infekcijom rotavirusa iz najmanje dva ne-G1 serotipa.
represents a hydrogen atom, a C1-C6 alkyl group, a C3-C6 cycloalkyl group, a C2-C6 alkenyl group, a C2-C6 alkynyl group, a halogen atom, a trifluoromethyl group, a difluoromethyl group, a cyano group, a C2-C7 alkylcarbonyl group, a C1-C6 alkylsulfonyl group, a nitro group, an amino group, a di(C1-C6 alkyl)amino group, a formyl group, a hydroxyl group, a C1-C6 alkoxy group, a C1-C6 alkylthio group, or a phenyl group or phenoxy group which may be substituted with 1 to 3 Ra's; 
predstavlja vodikov atom, skupinu C1-C6 alkil, skupinu C3-C6 cikloalkil, skupinu C2-C6 alkenil, skupinu C2-C6 alkinil, halogeni atom, trifluorometilnu skupinu, difluorometilnu skupinu, cijano skupinu, skupinu C2-C7 alkilkarbonil, skupinu C1-C6 alkilsulfonil, nitro skupinu, amino skupinu, skupinu di(C1-C6 alkil)amino, formil skupinu, hidroksil skupinu, skupinu C1-C6 alkoksi, skupinu C1-C6 alkiltio, ili fenilnu skupinu ili fenoksi skupinu koje mogu biti supstituirane s 1 do 3 Ra';
A method of producing corn plant seed containing a heterologous transgene insert that confers water deficit tolerance to a plant, said method comprising crossing a water deficit tolerant first parent corn plant comprising SEQ ID NO: 1, a heterologous transgenic insert comprising a truncated rice actin promoter that is operably linked to a cspB gene, and SEQ ID NO:2 with a second parent corn plant, wherein either the first or second parent corn plant is the female parent of the cross, and harvesting seed that comprise SEQ ID NO: 1, and the heterologous transgenic insert, and SEQ ID NO:2 from the female parent, thereby producing corn plant seed containing a heterologous transgene insert that confers water deficit tolerance to a plant. 
Prerađena hrana ili stočna hrana dobivena od sjemena kukuruza ima kromosom koji sadrži transgeni/genomski križani polinukleotid iz SEQ ID NO: 1 i heterologni transgeni umetak koji sadrži skraćeni riža-aktin promotor koji je operativno vezan na cspB gen, pri čemu se 5' terminalni kraj navedenog umetka preklapa sa 3' terminalnim krajem iz SEQ ID NO: 1, pri čemu spomenuta prerađena hrana ili stočna sadrži mjerljivu količinu polinukleotida koji obuhvaća nukleotidnu sekvencu iz SEQ ID NO: 1, SEQ ID NO: 2, ili njihov komplement. Prerađena hrana ili stočna hrana prema zahtjevu 8, pri čemu spomenuta hrana ili stočna hrana obuhvaća kukuruznu krupicu, kukuruzno brašno ili kukuruzni gluten.
Similarly prepared from (D)-isoleucine methyl ester hydrochloride 
Iz hidroklorida metilnog estera (D)-izoleucina slično se dobiva
Damage by the herbicidal compositions was evaluated with reference to a scale of 0% to 100% in comparison with untreated control plots. 
Oštećenje herbicidnim kompozicijama je procjenjivano u odnosu na skalu od 0% do 100% u usporedbi sa netretiranim kontrolnim biljkama.
The method of claim 13, wherein the fraction represents at least 0.1% of the human genome. The method of claim 13, wherein the fraction represents at least 0.5% of the human genome. 
Postupak prema zahtjevu 1, naznačen time, da frakcija predstavlja najmanje 0,1% ili najmanje 0,5% humanog genoma.
A weight distribution over the body is then determined by a computer system on the basis of the measured total weight and the measured outlines of the person. 
Metoda prema zahtjevu 1, naznačena time što se oblik bočnih 1 stražnjih obrisa tijela osobe određuje u stojećem položaju tijela.
Another alternative, as shown in Figure 2, has control 70 operatively connected to an intermediary component, here controller 80, which would translate the setting of control 70 into a signal that would instruct the speed of motor 42 through a cable, electrical wire, or other communication channel 82. 
Druga alternativa, kako je prikazano na slici 2, je komanda 70 povezana s jednom međukomponentom, ovdje kontrolorom 80, koji će prevesti položaj komande 70 u jedan signal koji će odrediti brzinu motora 42 kroz neki kabel, električnu žicu, ili drugi komunikacijski kanal 82.
The post-cure inflator 4 is disposed on the rear side of the vulcanizer main body 3 and is fixed to the guide frame 3a of the vulcanizer main body 3. 
Vulkanizator gume (1) u skladu s patentnim zahtjevom 5, naznačen time, da je uređaj za napuhavanje (4) fiksiran na glavno tijelo vulkanizatora (3).
A method for bonding of synthetic polymer nonwoven topsheet material of a sanitary napkin to synthetic polymer film backsheet material of said sanitary napkin according to claim 1, comprising the steps, (i)- pretreating corresponding regions of synthetic polymer nonwoven material by atmospheric pressure plasma, (ii)- optionally pretreating corresponding regions of synthetic polymer film by plasma, (iii)- applying adhesive or glue onto targeted regions of layer or layers, (iv)-joining said regions together. 
Metoda za vezivanje poliolefinskog netkanog materijala gornjeg sloja higijenskog uloška sa materijalom poleđine sa poliolefinskim filmom navedenog higijenskog uloška prema patentnom zahtjevu 1, koja obuhvaća korake, (i)- tretiranja odgovarajućih regija poliolefinskog netkanog materijala plazmom na atmosferskom pritisku, (ii)-opcionalnog tretiranja odgovarajućih regija poliolefinskog filma plazmom, (iii)- nanošenja adheziva ili ljepila na ciljane dijelove sloja ili slojeva, (iv)- spajanja navedenih regija zajedno.
The packaged product according to any one of claims 9, 11, or 12, or the MDO film according to any one of claims 10 to 12, wherein the MDO film has a tensile creep in the machine direction of about 0.10% to about 0.50% per µm thickness of the film, as measured in accordance with ISO 899-1-2003 with following conditions: sample width of 15 mm, grip distance of 100 mm, a load of 2300 g, 24 hours, and at 23°C. 
Pakirani proizvod u skladu s bilo kojim od patentnih zahtjeva 9, 11 ili 12, ili MDO film u skladu s bilo kojim od patentnih zahtjeva 10 do 12, naznačen time, da MDO film ima vrijednost vlačnog puzanja u smjeru stroja od oko 0,10% do oko 0,50% po um debljine filma, izmjereno u skladu s ISO 899-1-2003 pri sljedećim uvjetima: širina uzorka od 15 mm, udaljenost prihvata od 100 mm, opterećenje od 2300 g, 24 sata i na 23 °C.